Penumbra PEN
United StatesHealthcare · Medical DevicesUSD
361.58 USD (+14.3%)
12 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Penumbra is a medical device company that designs and markets innovative products for neurointervention and venous thrombectomy, with a model based on proprietary technology and direct sales to hospitals.
Key points
from its scores- ✓Very solid balance sheet7.7
- ✓Good share-price trend7.7
- ✓Favourable backdrop7.7
- ✕Demanding valuation1.4
- ✕Little or no dividend1.5
AI analysis
bottom line, main risk, context and newsBusiness quality and a clean balance sheet justify the premium, but the current multiple already discounts substantial growth and profitability is declining.
Penumbra combines a solid financial position (net cash of -2.18x EBITDA, liquidity of 5.75) with a 67.84% gross margin and 14.9% revenue growth, but its demanding valuation (P/E 77.73, EV/EBITDA 58.81) and falling earnings (-23.5%) limit near-term appeal.
The extreme valuation (P/E 77.73, EV/EBITDA 58.81) leaves little room for error: any disappointment in earnings growth could trigger a sharp correction, especially with earnings already down -23.5%.
Context and risks
No recent news or specific regulatory or geopolitical exposure identified for Penumbra. The macro interest rate environment does not materially affect a medical device company with net cash and 14.9% revenue growth.
Is Penumbra stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 249% above the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 77.7 | 26.7 | +191% |
| EV / EBITDA | 58.8 | 14.5 | +306% |
| Price / book | 8.1 | 4.1 | +98% |
| Price / sales | 8.3 | 3.4 | +142% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 1.4 out of 10 (median for Healthcare: 4.7).
Average analyst target: 361.58 USD, +14.3% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 6.5 (sector 5.5), Growth 4.4 (sector 6.6).
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 77.7
- Forward P/E
- 51.6
- EV / EBITDA
- 58.8
- Price / book
- 8.1
- Price / sales
- 8.3
- PEG
- 3.57
- Market cap
- 12.5B USD
- Enterprise value
- 12.0B USD
Profitability
- ROE
- 11.4%
- ROA
- 6.4%
- ROIC (approx.)
- 9.1%
- Gross margin
- 67.8%
- Operating margin
- 10.5%
- Net margin
- 10.7%
- Free cash flow
- 161.1M USD
- FCF yield
- 1.3%
- Cash conversion
- 79%
Solvency
- Total debt
- 212.7M USD
- Net debt
- −446.1M USD
- Cash
- 658.8M USD
- EBITDA
- 204.3M USD
- Net debt / EBITDA
- −2.18
- Debt / equity
- 13.90
- Current ratio
- 5.75
- Quick ratio
- 3.63
Growth
- Revenue growth
- +14.9%
- Earnings growth
- −23.5%
- EPS (TTM)
- 4.07 USD
- EPS (forward)
- 6.13 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- 0.70
- Analyst consensus
- Hold (12)
- Target price
- 361.58 USD
- 52-week range
- 221.26 – 362.41
Recent news
All PEN news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Penumbra
Is Penumbra stock cheap or expensive?
On P/E and EV / EBITDA, it trades 249% above the Healthcare median on average. Valuation score: 1.4 out of 10 (median for Healthcare: 4.7). Average analyst target: 361.58 USD, +14.3% versus the price. This is not investment advice.
What score does Penumbra get on MeridIAn Screener?
It scores 5.2 out of 10, rank 1,602 of 2,130 (better than 24% of the companies analysed). Its strongest category is Financial health (7.7) and its weakest, Valuation (1.4). Analysis of 08/10/2026.
What is Penumbra's P/E ratio?
Its P/E is 77.7: the share price equals 77.7 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 51.6.
How much is Penumbra worth on the stock market?
Its market capitalisation is 12.5B USD and its enterprise value, debt included, is 12.0B USD.
How much debt does Penumbra have?
It has more cash than debt: net cash of 446.1M USD.
Does Penumbra pay a dividend?
It pays no dividend, or almost none.
How has Penumbra stock performed over the last year?
It has risen 21.4% over the last year, excluding dividends. Over the last 52 weeks it has traded between 221.26 and 362.41 USD. Past performance does not guarantee future results.
What do analysts think of Penumbra?
12 analysts cover it; their average recommendation is “Hold” and their average target is 361.58 USD (+14.3% versus the price). It is an estimate, not market data.